A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition of CNV and Associated Inflammation and Fibrosis by VEGF Trap
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
PURPOSE: The exudative, or the wet form of age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). A subretinal Matrigel (BD Biosciences, Bedford MA) model of CNV is described here, along with the effects of vascular endothelial growth factor (VEGF) neutralization on the development of CNV and associated inflammation and fibrosis. METHODS: CNV was induced in adult Sprague-Dawley rats by subretinal injection of Matrigel. CNV growth and associated leukocyte infiltration and collagen deposition were examined. VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a recombinant protein that comprises portions of the extracellular domains of VEGF receptors 1 and 2 and that binds all isoforms of VEGF-A as well as placental growth factor with high affinity, was administered subcutaneously. RESULTS: Initiation of CNV was detected 4 days after Matrigel injection and then increased progressively in size. Systemic administration of VEGF Trap beginning on day 2 and 6 completely prevented development of CNV. When CNV was allowed to develop for 10 days before treatment was initiated, VEGF Trap not only prevented its further progression, but also induced substantial regression of existing lesions. In addition, VEGF Trap treatment reduced the total lesion volume and largely prevented the progressive leukocyte infiltration and fibrosis associated with CNV. CONCLUSIONS: The subretinal Matrigel CNV model provides a convenient tool for the study of the diverse components of complex CNV lesions. The data not only confirm the critical roles of VEGF in the development and maintenance of CNV, but further demonstrate that VEGF and other VEGF receptor 1 ligands promote CNV-associated inflammation and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Self-citationAgeing and degeneration in the macular region: A clinico-pathological study
Sarks, S. H. (1976) · British Journal of Ophthalmology · doi:10.1136/bjo.60.5.324 · Cited by 891
Oxidative damage-induced inflammation initiates age-related macular degeneration
Hollyfield, J. G., Bonilha, V. L., Rayborn, M. E., Yang, X., Shadrach, K. G., Lu, L., Ufret, R. L., Salomon, R. G., & Perez, V. L. (2008) · Nature Medicine · doi:10.1038/nm1709 · Cited by 710
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice
Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B. C., Kuziel, W. A., Rollins, B. J., & Ambati, B. K. (2003) · Nature Medicine · doi:10.1038/nm950 · Cited by 631
Sarks, J. P., Sarks, S. H., & Killingsworth, M. C. (1997) · Eye · doi:10.1038/eye.1997.137 · Cited by 140
Cited by
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Animal models of age related macular degeneration
Pennesi, M. E., Neuringer, M., & Courtney, R. J. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.003 · Cited by 391
“In light of its ability to mirror the subretinal deposit component of exudative AMD and its more lasting capacity to promote angiogenesis—either through sustained elution of angiogenic factors or recruitment of host cells—subretinal matrigel is an appealing model (Cao et al., 2010; Qiu et al., 2006).”
BackgroundMethodMechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382
“Species-appropriate VEGFA inhibitors potently prevent new vessel growth, control vessel permeability, and in some studies regress pathological vessels [28,43,44].”
BackgroundIndaram, M., Ma, W., Zhao, L., Fariss, R. N., Rodriguez, I. R., & Wong, W. T. (2015) · Scientific Reports · doi:10.1038/srep09144 · Cited by 101
Self-citation(2011) · Europe PMC (PubMed Central) · Cited by 55
Nork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.210 · Cited by 48
Peplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.295271 · Cited by 19
“CNV lesions in rats can be observed 4 days after Matrigel injection and they increase in size progressively for up to at least 20 days after Matrigel injection (Cao et al., 2010).”
BackgroundMethod
Metadata
- Authors
- Cao, J., Zhao, L., Li, Y., Liu, Y., Xiao, W., Song, Y., Luo, L., Huang, D., Yancopoulos, G. D., Wiegand, S. J., & Wen, R.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-11-01
- Volume
- 51
- Issue
- 11
- Pages
- 6009
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2061182836
- Cited by
- 92
- References
- 7
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.